High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 4, 2010, Pages 500-506

  Fox, Matthew P ^a,b   Ive, Prudence ^b   Long, Lawrence ^b   Maskew, Mhairi ^b,c   Sanne, Ian ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c RIGHT TO CARE   (South Africa)

Author keywords

Antiretroviral therapy; CD4 count; Human immunodeficiency virus; Second line therapy; South Africa; Sub Saharan Africa; Viral load

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA; SURVIVAL RATE; TREATMENT DURATION; VIROTHERAPY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PYRIMIDINONES; RITONAVIR; SOUTH AFRICA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 77949378464     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181bcdac1     Document Type: Article

References (22)

1. National Department of Health. National Antiretroviral Treatment Guidelines, 1st ed. Jacana; 2004.
2. Progress Report on Declaration of Commitment of HIV and AIDS. Republic of South Africa. Prepared for the United Nations General Assembly Special Session on HIV and AIDS. Department of Health, Republic of South Africa; 2008.
3. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
4. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
5. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38:14-17.
6. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224.
7. Lawn SD, Myer L, Wood R. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Clin Infect Dis. 2005;41:1683-1684.
8. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-147.
9. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36: 1009-1021.
10. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2007;44:453-455.
11. Vekemans M, John L, Colebunders R. When to switch for antiretroviral treatment failure in resource-limited settings? AIDS. 2007;21:1205-1206.
12. Galarraga O, O'Brien ME, Gutierrez JP, et al. Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. AIDS. 2007;21(Suppl 4):S97-S103.
13. Boyd MA, Cooper DA. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007;21(Suppl 4):S55-S63.
14. Renaud-Thery F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first-and second-line regimens. AIDS. 2007;21(Suppl 4):S89-S95.
15. Pujades-Rodriguez M, O'Brien D, Humblet P, et al. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS. 2008;22:1305-1312.
16. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
17. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-1134.
18. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4:e298.
19. Mocroft AJ, Lundgren JD, d'Armino MA, et al. Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol. 1997;26:400-407.
20. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603.
21. Maskew M, MacPhail P, Menezes C, et al. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J. 2007;97:853-857.
22. Dalal RP, MacPhail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2008;47: 101-107.